Carlos Alberto Ruiz
Research Subjects
Carlos Alberto Ruiz has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Edmund Chada Baracat
Laboratório de Ginecologia Estrutural e Molecular (LIM 58), Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil
3 shared publications - Francisco Pimentel Cavalcante
Hospital Geral de Fortaleza
3 shared publications - Guilherme Garcia Novita
Oncoclínicas, São Paulo, Brazil
3 shared publications - José Maria Soares Júnior
Laboratório de Ginecologia Estrutural e Molecular (LIM-58), Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia, Hospital das Clínicas HC-FMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo 05403-010, Brazil
3 shared publications - Ruffo Freitas-Junior
Universidade Federal de Goiás
3 shared publications - Adriana Magalhães de Oliveira Freitas
Florianopolis,Florianopolis,Brazil, Brazil
2 shared publications
Latest Publications
- Open Access
- 5 June 2026
- Published by MDPI AG in Preprints.org
MammaPrint™ Genetic Signature in the Brazilian Population, Analysis of Results and Clinical Outcomes (AGEMA-BRA) – Real World Study
Purpose: The MammaPrint™ (MP) 70-gene signature, identifies hormone receptor-positive (HR+), HER2-negative breast cancer patients with low genomic risk who are candidates for de-escalation of the systemic therapies employed. Knowing that MP was validated in an exclusively European cohort and understanding the heterogeneity of breast tumors in different populations, we proposed a study to analyze MP performance in the Brazilian population. Methods: Retrospective, prognostic evaluation, real-world cohort study of HR+, HER2- breast cancer patients who underwent MP in Brazil from January 2016 to December 2020 (AGEMA-BRA). Results: Of the 953 patients with high clinical risk, 407 (42.7%) had high genomic risk, and 546 (57.3%) had low genomic risk to MP. In the analysis of epidemiological, clinical, and anato-mopathological data correlating high and low risk to MP, and among the subgroups with low-risk, ultra-low risk, high-risk 1 and high-risk 2, only the histological grade showed statistical significance. Distant metastasis-free survival (DMFS) was 97.8% and overall survival (OS) was 99.8% with a mean follow-up of 40.8 months, with no difference between high and low genomic risk. Conclusions: Applying the MP signature in the AGEMA-BRA cohort enabled greater chemotherapy de-escalation with better DMFS than observed in the MINDACT pivotal study. Equivalent DMFS and OS results between high and low genomic risk carriers demonstrate the appropriate selection of patients by MP to receive or not receive adjuvant chemotherapy. These data make it possible to validate the performance of the signature in the Brazilian population and confirm the importance of testing it in different populations.
- 5 June 2026
- Published by MDPI AG in Preprints.org
Open AccessMammaPrint™ Genetic Signature in the Brazilian Population, Analysis of Results and Clinical Outcomes (AGEMA-BRA) – Real World Study
Purpose: The MammaPrint™ (MP) 70-gene signature, identifies hormone receptor-positive (HR+), HER2-negative breast cancer patients with low genomic risk who are candidates for de-escalation of the systemic therapies employed. Knowing that MP was validated in an exclusively European cohort and understanding the heterogeneity of breast tumors in different populations, we proposed a study to analyze MP performance in the Brazilian population. Methods: Retrospective, prognostic evaluation, real-world cohort study of HR+, HER2- breast cancer patients who underwent MP in Brazil from January 2016 to December 2020 (AGEMA-BRA). Results: Of the 953 patients with high clinical risk, 407 (42.7%) had high genomic risk, and 546 (57.3%) had low genomic risk to MP. In the analysis of epidemiological, clinical, and anato-mopathological data correlating high and low risk to MP, and among the subgroups with low-risk, ultra-low risk, high-risk 1 and high-risk 2, only the histological grade showed statistical significance. Distant metastasis-free survival (DMFS) was 97.8% and overall survival (OS) was 99.8% with a mean follow-up of 40.8 months, with no difference between high and low genomic risk. Conclusions: Applying the MP signature in the AGEMA-BRA cohort enabled greater chemotherapy de-escalation with better DMFS than observed in the MINDACT pivotal study. Equivalent DMFS and OS results between high and low genomic risk carriers demonstrate the appropriate selection of patients by MP to receive or not receive adjuvant chemotherapy. These data make it possible to validate the performance of the signature in the Brazilian population and confirm the importance of testing it in different populations.
- Open Access
Phyllodes tumors of the breast: A comprehensive review of diagnosis, treatment, and follow-up
Breast cancer and public healthcare: survey and proposals from Brazilian Society of Mastology (SBM)
Introduction: High rates of breast cancer mortality have been reported for patients from public healthcare, in Brazil. This study aimed to obtain a panorama of breast cancer in public healthcare, based on a questionnaire sent to breast specialists. Methods: Active members of the Brazilian Society of Mastology (SBM) were invited to participate anonymously, from Aug-Oct 2023. Possible answers ranged from “This is not a problem” to “This is a very serious, very common problem”. The primary endpoint of the study was the relative frequency of the answers. Results: Overall, 767 (44% of all SBM affiliated members) completed the questionnaire. Access to modern drugs was considered the most concerning problem, with 81.36% of respondents classifying this as “serious, frequently” or “very serious, very frequently”, followed by access to diagnostic methods (64.53%), access to breast reconstruction (60.24%), delay in starting treatment (60.11%) and access to screening (51.76%). Conclusions: This is the first study to evaluate the perceptions of breast specialists on breast cancer care within SUS. The SBM has issued considerations and proposals aimed at reestablishing a minimally adequate standard of breast cancer diagnosis and treatment in public healthcare in Brazil.
Breast cancer and public healthcare: survey and proposals from Brazilian Society of Mastology (SBM)
Introduction: High rates of breast cancer mortality have been reported for patients from public healthcare, in Brazil. This study aimed to obtain a panorama of breast cancer in public healthcare, based on a questionnaire sent to breast specialists. Methods: Active members of the Brazilian Society of Mastology (SBM) were invited to participate anonymously, from Aug-Oct 2023. Possible answers ranged from “This is not a problem” to “This is a very serious, very common problem”. The primary endpoint of the study was the relative frequency of the answers. Results: Overall, 767 (44% of all SBM affiliated members) completed the questionnaire. Access to modern drugs was considered the most concerning problem, with 81.36% of respondents classifying this as “serious, frequently” or “very serious, very frequently”, followed by access to diagnostic methods (64.53%), access to breast reconstruction (60.24%), delay in starting treatment (60.11%) and access to screening (51.76%). Conclusions: This is the first study to evaluate the perceptions of breast specialists on breast cancer care within SUS. The SBM has issued considerations and proposals aimed at reestablishing a minimally adequate standard of breast cancer diagnosis and treatment in public healthcare in Brazil.
- Open Access
- 22 November 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-12
Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology
Triple-negative breast cancer (TNBC) is a heterogenous subtype involving different patterns of behavior and clinical course, demanding a complex, individualized sequence of treatment. The knowledge and attitudes of the affiliated members of the Brazilian Society of Mastology regarding TNBC were evaluated and a consensus regarding management and treatment was reached. Affiliates completed a survey involving 44 objective questions. In addition, a specialist meeting was held with 27 experts and 3 ad hoc consultants. The panelists completed the survey before and after brainstorming. Answers achieving 70% of agreement were considered consensual. The chi-square test was used to compare answers between panelists and affiliates and the Kappa coefficient to calculate agreement. Consensus among the panelists increased from 26 (59.1%) to 32 questions (72.7%) following brainstorming (p = 0.17), including 7/10 questions on systemic treatment. Among the affiliates, consensus was achieved for 24 questions (54.5%), resulting in moderate agreement (κ = 0.445). Neoadjuvant chemotherapy should be indicated for almost all cases (except cT1a-b N0) and should include platinum agents. When indicated, immunotherapy is part of the standard of care. The panel reaffirmed the concept of no ink on tumor as indicative of adequate margins and the possibility of sentinel lymph node biopsy for cN1 patients who become cN0 following neoadjuvant therapy. Controversies remain on combining immunotherapy with capecitabine/olaparib in pertinent cases. Expert consensus was achieved for > 70% of the questions, with moderate agreement between panelists and affiliates. Educational interventions on systemic breast cancer treatment affected decision-making in 60% of the questions.
- 22 November 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-12
Open AccessManagement of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology
Triple-negative breast cancer (TNBC) is a heterogenous subtype involving different patterns of behavior and clinical course, demanding a complex, individualized sequence of treatment. The knowledge and attitudes of the affiliated members of the Brazilian Society of Mastology regarding TNBC were evaluated and a consensus regarding management and treatment was reached. Affiliates completed a survey involving 44 objective questions. In addition, a specialist meeting was held with 27 experts and 3 ad hoc consultants. The panelists completed the survey before and after brainstorming. Answers achieving 70% of agreement were considered consensual. The chi-square test was used to compare answers between panelists and affiliates and the Kappa coefficient to calculate agreement. Consensus among the panelists increased from 26 (59.1%) to 32 questions (72.7%) following brainstorming (p = 0.17), including 7/10 questions on systemic treatment. Among the affiliates, consensus was achieved for 24 questions (54.5%), resulting in moderate agreement (κ = 0.445). Neoadjuvant chemotherapy should be indicated for almost all cases (except cT1a-b N0) and should include platinum agents. When indicated, immunotherapy is part of the standard of care. The panel reaffirmed the concept of no ink on tumor as indicative of adequate margins and the possibility of sentinel lymph node biopsy for cN1 patients who become cN0 following neoadjuvant therapy. Controversies remain on combining immunotherapy with capecitabine/olaparib in pertinent cases. Expert consensus was achieved for > 70% of the questions, with moderate agreement between panelists and affiliates. Educational interventions on systemic breast cancer treatment affected decision-making in 60% of the questions.
- Open Access
- 11 August 2020
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17 (16) , 5804
Health Services, Socioeconomic Indicators, and Primary Care Coverage in Mortality by Lower Genital Tract and Breast Neoplasias in Brazilian Women during Reproductive and Non-Reproductive Periods
Women’s health assistance at the low-complexity level is focused on the most common diseases and can be affected by primary health care coverage, particularly in areas far away from large urban centers. Thus, in this work, we aim to analyze the relationship between socioeconomic status, health care indicators, and primary care coverage in mortality from neoplasms of the lower genital tract and breast in Brazilian women during reproductive and non-reproductive periods. We conducted an ecological study at the Gynecology Discipline, Medicine School, University of São Paulo. Secondary data were collected from women according to reproductive periods and mortality data from the Mortality Information System based on International Classification of Disease—10th edition regarding breast and lower genital tract neoplasms in 2017. The health service and socioeconomic indicators were obtained from the Informatics Department of the Unified Health System and Brazilian Institute of Geography and Statistics. Our results showed that primary care coverage and health service indicators were not associated with mortality from breast cancer and the female lower genital tract, both in reproductive and non-reproductive periods. Sociodemographic indicators were found to be associated with mortality from breast cancer and the female lower genital tract, with income being associated with reproductive period (β = −0.4; 95% CI, −0.8 to −0.03) and educational level in the non-reproductive period (β = 9.7; 95% CI, 1.5 to 18.0).
- 11 August 2020
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17 (16) , 5804
Open AccessHealth Services, Socioeconomic Indicators, and Primary Care Coverage in Mortality by Lower Genital Tract and Breast Neoplasias in Brazilian Women during Reproductive and Non-Reproductive Periods
Women’s health assistance at the low-complexity level is focused on the most common diseases and can be affected by primary health care coverage, particularly in areas far away from large urban centers. Thus, in this work, we aim to analyze the relationship between socioeconomic status, health care indicators, and primary care coverage in mortality from neoplasms of the lower genital tract and breast in Brazilian women during reproductive and non-reproductive periods. We conducted an ecological study at the Gynecology Discipline, Medicine School, University of São Paulo. Secondary data were collected from women according to reproductive periods and mortality data from the Mortality Information System based on International Classification of Disease—10th edition regarding breast and lower genital tract neoplasms in 2017. The health service and socioeconomic indicators were obtained from the Informatics Department of the Unified Health System and Brazilian Institute of Geography and Statistics. Our results showed that primary care coverage and health service indicators were not associated with mortality from breast cancer and the female lower genital tract, both in reproductive and non-reproductive periods. Sociodemographic indicators were found to be associated with mortality from breast cancer and the female lower genital tract, with income being associated with reproductive period (β = −0.4; 95% CI, −0.8 to −0.03) and educational level in the non-reproductive period (β = 9.7; 95% CI, 1.5 to 18.0).